The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
September 9th 2025
This article reviews the safety, efficacy, and regulatory concerns related to compounded semaglutide, with a focus on how health care providers can offer guidance and education to patients.
September 8th 2025
Experimental RNA Therapy Significantly Reduces Blood Pressure up to 6 Months, Study Says
February 18th 2024Researchers said these findings confirm that zilebesiran can significantly reduce serum angiotensinogen levels, leading to sustained reductions in blood pressure over a 24-hour period, even 6 months post-treatment, though more research is needed for longer-term use.
Read More
Hospitalized Children With Diabetes May Be Able to Continue Safe Use of Home Pumps, Suggest Findings
February 17th 2024Using home insulin pumps when hospitalized was relatively safe compared with hospital-managed pumps and insulin injections among more than 2700 children admitted to a single hospital center.
Read More
Combination Therapies Provide Optimal Hypertensive Control in Patients Taking Ibrutinib
February 17th 2024The retrospective study found patients on Bruton’s tyrosine kinase inhibitors are similar to the general population in the sense that it usually takes at least 2 anti-hypertensive drugs to control blood pressure.
Read More
Elacestrant: Treatment Considerations, Including Dosing and Compliance
February 16th 2024Experts explore treatment considerations when treating patients with metastatic breast cancer with elacestrant, including dosing, patient selection, adherence, and treatment duration. Participants also discuss dose modifications, adherence concerns, and how they determine treatment failure.
Watch
Daratumumab-Based Regimen Potential Promising Bridging Therapy for RRMM
February 15th 2024The combination of daratumumab and immumodulatory therapy was evaluated among patients with relapsed/refractory multiple myeloma (RRMM) who have failed prior treatment with immunomodulatory agents, proteasome inhibitors, and daratumumab as monotherapy or in combination.
Read More
Vyvgart Phase 3 Extension Study Data Affirm Long-Term Safety, Efficacy in gMG
February 15th 2024Details from the final interim data analysis of the ADAPT+ study confirm previous findings seen with efgartigimod (Vyvgart) in generalized myasthenia gravis (gMG), the rare neuromuscular autoimmune disease.
Read More
The Federal Trade Commission and HHS will examine generic drug shortage causes; the Biden administration recently dedicated an additional $515 million to a major initiative to study long COVID; cybersecurity experts warn that US hospitals are at risk for attacks and the government is doing little to prevent such breaches.
Read More
In Adolescents With Obesity, FMT Shows No Negative Impact on Horizontal Gene Transfer
February 15th 2024For this analysis, investigators used metagenomic sequencing files from the Gut Bugs trial, a placebo-controlled multidonor fecal microbiota transplantation (FMT) trial conducted among adolescents classified as obese.
Read More
Registry Reveals Sex Differences in HoFH Diagnosis, Treatment, and Cardiovascular Outcomes
February 15th 2024Although the prevalence of myocardial infarction (MI) was doubled among men compared with women with homozygous familial hypercholesterolemia (HoFH), both sexes had similar ages at first MI.
Read More
Nutritional Intervention May Improve Outcomes but Is Underresearched in Ovarian Cancer
February 14th 2024A recent review suggests patients diagnosed with ovarian cancer may benefit from nutritional intervention as part of disease management, but research on the topic has been limited and further investigation is warranted.
Read More
Bundling Interventions to Promote CRC, SDOH Screenings Found Feasible, Effective
February 14th 2024Combining interventions to encourage screenings for colorectal cancer (CRC) and social determinants of health (SDOH) was found to improve screening rates in CRC without decreasing rates of screenings for SDOH.
Read More
Part of the recent Medicare reimbursement cuts could be addressed in a spending package next month; Medicaid/Medicare dual eligibles are expected to generate big profits for health insurers; FDA sent warning letters to online vendors selling unapproved and misbranded versions of semaglutide and tirzepatide.
Read More
Durvalumab Consolidation Therapy Shows Promise in Elderly Patients With Stage III NSCLC
February 12th 2024Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.
Read More
Meta-Analysis Highlights Differing CAR T Outcomes, Toxicities in Relapsed or Refractory DLBCL
February 12th 2024A real-world comparison of 2 chimeric antigen receptor (CAR) T-cell therapies—axicabtagene ciloleucel and tisagenlecleucel—suggests the former is associated with better efficacy but higher toxicity.
Read More